Drug intelligence / Profile preview

CRS-207 + cisplatin + cyclophosphamide + pemetrexed

Development stage: Phase 1
Lead developer: Novartis
Modality: Vaccines & Immunotherapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of CRS-207 (a live-attenuated Listeria monocytogenes vaccine engineered to express mesothelin), cisplatin (a platinum-based chemotherapy agent), cyclophosphamide (an alkylating agent used as an immunomodulator), and pemetrexed (a folate analog chemotherapy agent). This combination is designed to treat malignant pleural mesothelioma (MPM) by combining immunotherapy with standard chemotherapy. CRS-207 stimulates both innate and adaptive immunity against mesothelin, a tumor-associated antigen highly expressed in MPM, while low-dose cyclophosphamide is used to enhance immune responses. The chemotherapy components (cisplatin and pemetrexed) provide direct cytotoxic effects against cancer cells.

Other names: CRS-207 with cyclophosphamide and pemetrexed/cisplatin

Targets

DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)MesothelinTS (Thymidylate synthase)

Beyond the preview

Go deeper on CRS-207 + cisplatin + cyclophosphamide + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRS-207 + cisplatin + cyclophosphamide + pemetrexed.